第34届亚太肝脏研究协会（Asian-Pacific Association for the Study of the Liver，APASL）年会将于3月26日至3月30日在北京盛大启幕。目前会议摘要标题已公布，医脉通肿瘤科特别整理了肝胆胰肿瘤领域的中国Later Breaker和Oral研究，与读者一同抢先聆听中国强音的前奏。
Later Breaker
1. 标题：Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma: Interim Analysis of An Open-label, Multi-center Phase IIIb Study (TREMENDOUS study)
Submit ID：16632
New-ID：LB0003
报告人：樊嘉
单位：复旦大学附属中山医院
报告时间：3月28日08:00-08:48
Oral
1. 标题：Tertiary lymphoid structures in hepatocellular carcinoma: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy
Submit ID：15942
New-ID：AA0004
报告人：JiaYong Su
报告时间：3月26日13:35-15:05
2. 标题：Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression
Submit ID：15480
New-ID：AA0019
报告人：Jinqiu Zhao
报告时间：3月26日13:35-15:05
3. 标题：Single-cell Spatial Proteomic Landscape of Intrahepatic Cholangiocarcinoma Immune Microenvironment Reveals Immune Evasion via FSTL1-negative Macrophage
Submit ID：15701
New-ID：AA0021
报告人：Wenzhu Li
报告时间：3月26日13:35-15:05
4. 标题：Coordination of Solute Carrier Family 39 Member 1 and Dynamin-related Protein 1 Facilitates Hepatocellular Carcinoma Recurrence by Impairing Mitochondrial Quality Control
Submit ID：14471
New-ID：AA0022
报告人：RUI LI
报告时间：3月26日13:35-15:05
5. 标题：HBV replication facilitates drug resistance of hepatocellular carcinoma via CD133 regulating self-renewal of liver cancer stem cells
Submit ID：12891
New-ID：AA0029
报告人：Kuanhui Xiang
报告时间：3月26日13:35-15:05
6. 标题：Disease time burden in patients with advanced hepatocellular carcinoma receiving systemic therapy
Submit ID：15225
New-ID：AA0044
报告人：Matthew ShingHin Chung
单位：香港大学李嘉诚医学院
报告时间：3月26日13:35-15:05
7. 标题：A retrospective study of immune checkpoint inhibitors-based combination therapy in patients with HCC for liver injury
Submit ID：16234
New-ID：AA0047
报告人：Luping Lin
报告时间：3月26日13:35-15:05
8. 标题：Targeted Therapy with GPC3-Loaded Exosomes: IR780-Based Thermotherapy and Lenvatinib Chemotherapy in Hepatocellular Carcinoma
Submit ID：13313
New-ID：OP0009
报告人：Shenan Huang
报告时间：3月28日13:15-14:15
9. 标题：CXCL2 Potentiates Neutrophil-mediated Anti-tumor Immunity by Inhibiting Cholesterol Biosynthesis in Hepatocellular Carcinoma
Submit ID：14251
New-ID：OP0010
报告人：Xin Liu
报告时间：3月28日13:15-14:15
10. 标题：A Multi-institutional Analysis of Risk Factors and Predictive Model for Distant Metastasis After Hepatic Resection for Hepatocellular Carcinoma
Submit ID：14343
New-ID：OP0011
报告人：杨田
单位：海军军医大学第三附属医院（东方肝胆外科医院）
报告时间：3月28日13:15-14:15
11. 标题：HCC risk stratification for cirrhosis patients: integrating radiomics and deep learning CT signatures of liver and spleen into clinical model
Submit ID：14437
New-ID：OP0012
报告人：Yaru Shi
报告时间：3月28日13:15-14:15
12. 标题：CHEK1 suppresses hepatocellular carcinoma progression by modulating reprogramming of tumor-associated macrophages
Submit ID：14588
New-ID：OP0038
报告人：Yanqiu Li
报告时间：3月28日14:15-15:15
13. 标题：Revisiting AASLD Guidelines: A Real-world Analysis of Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Patients
Submit ID：11809
New-ID：OP0039
报告人：Yue Huang
报告时间：3月28日14:15-15:15
14. 标题：Pathological Study of the Tumor Microenvironment After Neoadjuvant Therapy in Hepatocellular Carcinoma: Why Does TACE Combined with Anti-Angiogenics and Immunotherapy Outperform TACE Alone?
Submit ID：15334
New-ID：OP0041
报告人：Xintao He
报告时间：3月28日14:15-15:15
15. 标题：Classifications and Outcomes of Local Tumor Progression of Hepatocellular Carcinoma after Thermal Ablation: A Longitudinal Multicenter Study
Submit ID：15354
New-ID：OP0042
报告人：Fangying Fan
报告时间：3月28日14:15-15:15
16. 标题：An ultrasound-based interpretable machine learning model for the classification of small hepatocellular carcinoma
Submit ID：15352
New-ID：OP0067
报告人：Fangying Fan
报告时间：3月28日15:30-16:30
17. 标题：Efficacy and Safety of Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Retrospective, Multicenter Cohort Study
Submit ID：15826
New-ID：OP0068
报告人：JingKun Chen
报告时间：3月28日15:30-16:30
18. 标题：The Impact and Mechanisms of Neurofibromin 1 (NF1) on the Progression of Intrahepatic Cholangiocarcinoma
Submit ID：15849
New-ID：OP0069
报告人：Zhengfeng Xuan
报告时间：3月28日15:30-16:30
19. 标题：Impact of Immune-Related Adverse Events on Survival in the Immunotherapy of Advanced Hepatocellular Carcinoma
Submit ID：16583
New-ID：OP0070
报告人：Nan Zhang
报告时间：3月28日15:30-16:30
20. 标题：Efficacy and safety of pembrolizumab and lenvatinib in combination with GEMOX via different administration routes (HAIC vs intravenous) in advanced intrahepatic cholangiocarcinoma: a retrospective analysis of real-world evidence
Submit ID：16541
New-ID：OP0071
报告人：Hongli Yu
报告时间：3月28日15:30-16:30
21. 标题：Retrospective Analysis of Efficacy Differences Between Lenvatinib and Sorafenib in Patients with Mid-to-Late Stage Hepatocellular Carcinoma Complicated by Diabetes
Submit ID：16538
New-ID：OP0072
报告人：jiaqi Liu
报告时间：3月28日15:30-16:30
22. 标题：Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy for Systemic Chemotherapy Refractory Pancreatic Cancer with Liver Metastases
Submit ID：16549
New-ID：OP0098
报告人：Yaqin Wang
报告时间：3月28日16:30-17:30
23. 标题：Oncolytic virus M1-c6v1 combined with camrelizumab and apatinib in patients with advanced hepatocellular carcinoma: A phase 2 open-label trial evaluating safety, and efficacy
Submit ID：15595
New-ID：OP0099
报告人：谢婵
单位：中山大学附属第三医院
报告时间：3月28日16:30-17:30
24. 标题：A multicenter case–controlled study on laparoscopic hepatectomy versus microwave ablation as first-line therapy for 3–5 cm hepatocellular carcinoma in patients aged 60 and older
Submit ID：15150
New-ID：OP0101
报告人：Zhen Wang
报告时间：3月28日16:30-17:30
25. 标题：Efficacy and safety of tremelimumab plus durvalumab in participants from mainland of China with unresectable hepatocellular carcinoma: extension cohort of the randomized, open-label, multicenter, global, Phase 3 HIMALAYA study
Submit ID：13349
New-ID：OP0102
报告人：秦叔逵
单位：中国药科大学附属南京天印山医院
报告时间：3月28日16:30-17:30
26. 标题：Survival benefit from neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors for resectable intermediate or advanced hepatocellular carcinoma (GUIDANCE002): a multicenter, retrospective study
Submit ID：15890
New-ID：OP0161
报告人：DaLong Yang
报告时间：3月29日10:00-11:00
27. 标题：Worldwide burden of liver cancer due to metabolic dysfunction-associated steatohepatitis from 1990 to 2019: insights from the Global Burden of Disease study
Submit ID：16561
New-ID：OP0176
报告人：Minshan Huang
报告时间：3月29日10:00-11:00
28. 标题：Burden of pancreatic cancer and its attributable risk factors in 204 countries and territories, 1990-2021: results from the Global Burden of Disease Study 2021
Submit ID：16731
New-ID：OP0177
报告人：姜凯
单位：中国人民解放军总医院
报告时间：3月29日10:00-11:00
29. 标题：Circulating Tumor-specific Cell-free Tumor DNA is Useful in Monitoring Recurrence of HBV-related HCC after Liver Transplantation
Submit ID：16758
New-ID：OP0189
报告人：叶秀慧
单位：台湾大学医学院
报告时间：3月29日11:00-12:00
30. 标题：Effectiveness and Safety of Atezolizumab Combined with Lenvatinib as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma: a Retrospective Study
Submit ID：15340
New-ID：OP0218
报告人：Ying Luo
报告时间：3月29日13:30-14:30
31. 标题：AI-Enhanced Tumor Volume Assessment for Hepatocellular Carcinoma Treatment Efficacy: A Superior Alternative to Diameter-Based Evaluation Criteria
Submit ID：11380
New-ID：OP0220
报告人：Dianzhe Tian
报告时间：3月29日13:30-14:30
32. 标题：Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a multi-center cohort study
Submit ID：11786
New-ID：OP0221
报告人：Wang Yong Shuai
单位：中国科学技术大学附属第一医院
报告时间：3月29日13:30-14:30
33. 标题：AKR1B10 as a New Diagnostic and Prognostic Serum Marker for Hepatocellular Carcinoma
Submit ID：13300
New-ID：OP0222
报告人：曹德良
单位：南华大学
报告时间：3月29日13:30-14:30
34. 标题：Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy
Submit ID：13572
New-ID：OP0247
报告人：Bixing Zhao
单位：福建医科大学孟超肝胆医院
报告时间：3月29日14:30-15:30
35. 标题：4-hydroxyhippuric acid drives SLC22A4+ neutrophils to deteriorate CD8+T cell anti-tumor immunity in hepatocellular carcinoma
Submit ID：14010
New-ID：OP0249
报告人：Hanyi Zeng
报告时间：3月29日14:30-15:30
36. 标题：Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma
Submit ID：14727
New-ID：OP0250
报告人：Liying Ren
报告时间：3月29日14:30-15:30
37. 标题：Efficacy and Safety of the Combination of Envafolimab and Lenvatinib in Unresectable Hepatocellular Carcinoma: a Single-arm, Multicentre, Exploratory Phase II Clinical Study
Submit ID：14797
New-ID：OP0251
报告人：韩云炜
单位：西南医科大学附属医院
报告时间：3月29日14:30-15:30
38. 标题：A Pilot Study of Adoptive Natural Killer Cell Therapy Combined with Microwave Ablation for Hepatocellular Carcinoma
Submit ID：15486
New-ID：OP0252
报告人：Qian Cai
报告时间：3月29日14:30-15:30
39. 标题：Effects of Nucleoside analogues on liver fibrosis remission in patients with HBV-related hepatocellular carcinoma
Submit ID：16161
New-ID：OP0263
报告人：JianRong Li
单位：西南医科大学附属医院
报告时间：3月29日14:30-15:30
40. 标题：Ethanol decreases CPT2-mediated Carnitine catabolism to promote stemness in alcoholic hepatocellular carcinoma
Submit ID：14151
New-ID：OP0269
报告人：Xiaoxue Yuan
报告时间：3月29日14:30-15:30
41. 标题：Early Diagnosis of HBV-related HCC: Application of Liquid Biopsy Technology Based on DNA Methylation
Submit ID：15132
New-ID：OP0281
报告人：Xueying Huang
报告时间：3月29日15:45-16:45
42. 标题：Baohuoside I inhibits Hepatocellular carcinoma through the UBE2C/P53 Pathway
Submit ID：16524
New-ID：OP0289
报告人：Xin Zhang
报告时间：3月29日15:45-16:45
43. 标题：Efficacy and Safety of He-Shu-Xiao-Ji Pill Combined with Standard Treatment Strategy in HBV-related Hepatocellular Carcinoma: A Single-center, Prospective Control, Real-world Cohort Study
Submit ID：16506
New-ID：OP0293
报告人：朱晓宁
单位：西南医科大学附属中医医院
报告时间：3月29日15:45-16:45
44. 标题：Efficacy and safety of SIRT combined with low-dose HAIC, tyrosine kinase inhibitors, and immune checkpoint inhibitors for unresectable large hepatocellular carcinoma
Submit ID：15131
New-ID：OP0307
报告人：Mingzhi Hao
报告时间：3月29日16:45-17:45
45. 标题：Multicohort fecal metagenomes analysis contributes to non-invasive diagnosis for cholangiocarcinoma
Submit ID：15388
New-ID：OP0308
报告人：任志刚
单位：复旦大学附属肿瘤医院
报告时间：3月29日16:45-17:45
46.标题：Decade-Long Survival Insights: Upfront Ablation Outperforms Delayed Ablation in Colorectal Liver Oligometastases: A Comprehensive Nationwide Study
Submit ID：16649
New-ID：OP0309
报告人：Jianming Li
报告时间：3月29日16:45-17:45
47. 标题：Hepatic Adverse Events of Novel Immunotherapy-Based Therapies in Clinical Trials: A Systematic Review and Meta-Analysis
Submit ID：15325
New-ID：OP0324
报告人：Minyan Ye
报告时间：3月29日16:45-17:45
48. 标题：Sorafenib plus transarterial chemoembolization versus sorafenib alone in advanced hepatocellular carcinoma (SELECT): a multicenter, phase 3, randomized, controlled trial
Submit ID：15010
New-ID：OP0327
报告人：Yan Zhao
报告时间：3月29日16:45-17:45
49. 标题：The Efficacy and Safety of Pegylated Interferon Alpha Treatment in Patients with HBV Related Cirrhosis and HCC after Radical Surgery: Preliminary Data From The TERMINATOR Project
Submit ID：15456
New-ID：OP0332
报告人：窦晓光
单位：中国医科大学附属盛京医院
报告时间：3月29日16:45-17:45
50. 标题：Gut-liver axis modulation empowers natural killer T cells for liver cancer immunotherapy
Submit ID：16709
New-ID：OP0337
报告人：Ting Luo
报告时间：3月30日08:00-09:00
51. 标题：Predictive Value of pgRNA for Recurrence in Advanced Hepatocellular Carcinoma and Its Potential Mechanisms
Submit ID：14050
New-ID：OP0341
报告人：Yifan Han
报告时间：3月30日09:00-10:00
52. 标题：PHGDH acts as an RNA-binding protein to stabilize PRKCD mRNA and promote hepatocellular carcinoma progression
Submit ID：13414
New-ID：OP0343
报告人：bin cheng
报告时间：3月30日09:00-10:00
53. 标题：Long Noncoding RNA FTX Exhibits Dual Roles in Hepatocellular Carcinoma Progression: Implications for Anoikis Resistance and Metastasis
Submit ID：15528
New-ID：OP0345
报告人：Tao Li
报告时间：3月30日09:00-10:00
54. 标题：Detection of MVI in HCC using spatiotemporal radiomics of contrast-enhanced ultrasound: a deep learning model with transcriptomics correlation
Submit ID：14963
New-ID：OP0384
报告人：逄川
单位：解放军总医院第五医学中心
报告时间：3月30日10:00-11:00
55. 标题：Assessment of the Diagnostic Efficacy of a Novel Liver Cancer Biomarker: Multigene Methylation
Submit ID：15148
New-ID：OP0385
报告人：Xiangsha Kong
报告时间：3月30日10:00-11:00
56. 标题：A Novel Mitochondrial Micropeptide HRMM1 Interacts with ATP5B to Promote Energy Metabolism and Hepatocellular Carcinoma Progression
Submit ID：13894
New-ID：OP0389
报告人：Wenli Xu
报告时间：3月30日10:00-11:00
57. 标题：The role and pathogenesis of hydrogen sulfide in angiogenesis of HCC vascularized organoid
Submit ID：15357
New-ID：OP0392
报告人：Lingna Lyu
报告时间：3月30日10:00-11:00
58. 标题：SCG101 TCR-T Therapy Achieves Rapid and Sustained HBsAg Reduction with >30% HBsAg Loss in HBV-Related Hepatocellular Carcinoma Patients
Submit ID：15125
New-ID：PL0014
报告人：Shunda Du
报告时间：3月29日13:30-15:00
59. 标题：Hepatic TM6SF2 activates anti-tumor immunity to suppressed metabolic dysfunction-associated steatotic liver disease–associated hepatocellular carcinoma and boosts immunotherapy
Submit ID：15526
New-ID：YI0009
报告人：Yating ZHANG
报告时间：3月29日11:00-12:00
60. 标题：Prognostic Discordance Among Five Major Staging Systems for Early-stage Hepatocellular Carcinoma: A Multi-institutional Analysis of 4,623 Patients
Submit ID：14375
New-ID：YI0016
报告人：杨田
单位：海军军医大学第三附属医院（东方肝胆外科医院）
报告时间：3月29日11:00-12:00
61. 标题：Microwave Ablation versus Repeat Liver Resection for Recurrent Intrahepatic Cholangiocarcinoma within Milan Criteria: A Long-term Multicenter Cohort Study
Submit ID：14964
New-ID：YI0024
报告人：逄川
单位：解放军总医院第五医学中心
报告时间：3月30日08:00-09:00
62. 标题：Outcomes of Conversion Surgery After Immune Checkpoint Inhibitor-Based Combination Therapy in Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
Submit ID：16537
New-ID：YI0025
报告人：Mingjian Piao
报告时间：3月30日08:00-09:00
63. 标题：Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors
Submit ID：11835
New-ID：YI0029
报告人：Yingcheng Wu
报告时间：3月30日08:00-09:00
备注：排名不分先后，按照摘要号进行，如有遗漏或任何问题，请给我们留言~
(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)
